Novo Nordisk Stock Plunges and Eli Lilly Jumps. It's All Down to This Weight-Loss Drug Trial.

Novo shares slump after the Danish drugmaker's experimental obesity drug fails to beat Lilly's treatment in an 84-week trial. ...